These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 25228556)

  • 21. How to manage acute promyelocytic leukemia.
    Mi JQ; Li JM; Shen ZX; Chen SJ; Chen Z
    Leukemia; 2012 Aug; 26(8):1743-51. PubMed ID: 22422168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D; Mistry AR; Solomon E; Guidez F
    Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and treatment of acute promyelocytic leukemia.
    Jurcic JG; Soignet SL; Maslak AP
    Curr Oncol Rep; 2007 Sep; 9(5):337-44. PubMed ID: 17706161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
    Chim CS; Kwong YL; Liang R; Chu YC; Chan CH; Chan LC; Wong KF; Chan TK
    Hematol Oncol; 1996 Sep; 14(3):147-54. PubMed ID: 9119359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expanding role of arsenic in acute promyelocytic leukemia.
    Tallman MS
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S25-9. PubMed ID: 18760708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
    Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute promyelocytic leukemia with the translocation t(15;17)(q22;q21) associated with t(1;2)(q42~43;q11.2~12): a case report.
    Wafa A; Moassass F; Liehr T; Al-Ablog A; Al-Achkar W
    J Med Case Rep; 2016 Jul; 10():203. PubMed ID: 27459859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the role of arsenic in newly diagnosed APL?
    Tallman MS
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications.
    He LZ; Merghoub T; Pandolfi PP
    Oncogene; 1999 Sep; 18(38):5278-92. PubMed ID: 10498880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
    Tong H; Li K; Mei C; Wang H; Chen Z; Jin J
    Ann Hematol; 2011 Dec; 90(12):1493-4. PubMed ID: 21431323
    [No Abstract]   [Full Text] [Related]  

  • 31. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
    Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
    Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autophagic degradation of an oncoprotein.
    Bøe SO; Simonsen A
    Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinoic acid and arsenic for treating acute promyelocytic leukemia.
    Zhou GB; Zhao WL; Wang ZY; Chen SJ; Chen Z
    PLoS Med; 2005 Jan; 2(1):e12. PubMed ID: 15696202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors.
    Avvisati G; Lo Coco F; Mandelli F
    Semin Hematol; 2001 Jan; 38(1):4-12. PubMed ID: 11172535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A study on the relationship between morphology and gene heterogeneity in acute promyelocytic leukemia].
    Xiong S; Chen Z; Huang W
    Zhonghua Nei Ke Za Zhi; 1995 Mar; 34(3):165-8. PubMed ID: 7648936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application.
    Wang Z; Sun G; Shen Z; Chen S; Chen Z
    Chin Med J (Engl); 1999 Nov; 112(11):963-7. PubMed ID: 11721474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction.
    Hu J
    Front Med; 2011 Mar; 5(1):45-52. PubMed ID: 21681674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinoid differentiation therapy in promyelocytic leukemia.
    Chomienne C; Fenaux P; Degos L
    FASEB J; 1996 Jul; 10(9):1025-30. PubMed ID: 8801163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia.
    Ganzel C; Douer D; Tallman MS
    J Natl Compr Canc Netw; 2013 Dec; 11(12):1512-21. PubMed ID: 24335686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.